BACKGROUND/AIMS: To examine eukaryotic elongation factor1A2 (eEF1A2) expression in pancreatic ductal adenocarcinoma (PDA) and to analyze its relationship with the clinicopathol¬ogy of PDA. METHODOLOGY: eEF1A2 expression was examined in 97 PDA specimens by immunohistochemistry. We also analyzed the association between FAP expression in PDAC cells and the clinicopathology of PDA patients. RESULTS: eEF1A2 expression was absent in normal pancreatic tissue. In contrast, in PDA, eEF1A2 showed positive immunoreactivity in 76 of 97 (77.8%) PDA cases. We found significant associations between increased eEF1A2 expression and the presence of nodal metastasis (p=0.039) and perineural invasion (p=0.043). Univariate analysis of survival showed that the median overall survival time of eEF1A2-positive PDA patients (11.7 months) was significantly shorter than that of eEF1A2-negative PDAC patients (17.5 months; p<0.001). In addition, when the Cox proportion hazard model was used in multivariate survival analysis, we revealed that eEF1A2 expression (p<0.001; hazard rate, 95%CI 2.91-13.61) and TNM stage (p<0.001 hazard rate, 95%CI 0.18-0.23) still remained statistically significant. CONCLUSIONS: eEF1A2 is highly expressed in PDA, and its expression is associated with nodal metastasis and perineural invasion, as well as worse prognosis.
BACKGROUND/AIMS: To examine eukaryotic elongation factor1A2 (eEF1A2) expression in pancreatic ductal adenocarcinoma (PDA) and to analyze its relationship with the clinicopathol¬ogy of PDA. METHODOLOGY:eEF1A2 expression was examined in 97 PDA specimens by immunohistochemistry. We also analyzed the association between FAP expression in PDAC cells and the clinicopathology of PDA patients. RESULTS:eEF1A2 expression was absent in normal pancreatic tissue. In contrast, in PDA, eEF1A2 showed positive immunoreactivity in 76 of 97 (77.8%) PDA cases. We found significant associations between increased eEF1A2 expression and the presence of nodal metastasis (p=0.039) and perineural invasion (p=0.043). Univariate analysis of survival showed that the median overall survival time of eEF1A2-positive PDA patients (11.7 months) was significantly shorter than that of eEF1A2-negative PDAC patients (17.5 months; p<0.001). In addition, when the Cox proportion hazard model was used in multivariate survival analysis, we revealed that eEF1A2 expression (p<0.001; hazard rate, 95%CI 2.91-13.61) and TNM stage (p<0.001 hazard rate, 95%CI 0.18-0.23) still remained statistically significant. CONCLUSIONS:eEF1A2 is highly expressed in PDA, and its expression is associated with nodal metastasis and perineural invasion, as well as worse prognosis.
Authors: Thomas Stefan Worst; Frank Waldbillig; Abdallah Abdelhadi; Cleo-Aron Weis; Maria Gottschalt; Annette Steidler; Jost von Hardenberg; Maurice Stephan Michel; Philipp Erben Journal: BMC Urol Date: 2017-09-18 Impact factor: 2.264